Journal article
A pharmacogenomics primer
Journal of clinical pharmacology, Vol.47(9), pp.1087-1103
09/2007
Handle:
https://hdl.handle.net/2376/114138
PMID: 17664254
Abstract
The human genome project and related research initiatives have enabled the identification of a significant number of genetic variants that are predictive of drug response and outcome (pharmacogenomic biomarkers). As yet, incorporation of routine pharmacogenomic testing into clinical practice has been relatively modest. Potential barriers to adoption include a relative lack of prospective controlled trials establishing the benefits of such testing, economic constraints, and ethical concerns, among others. Clinicians considering the use of pharmacogenomic testing in their practice also may be unfamiliar with the concepts and principles underlying this rapidly evolving discipline. Consequently, the purpose of this review is to provide the clinical pharmacologist with a primer on the principles and molecular mechanisms underlying pharmacogenomics. In addition, the methods currently being used to discover novel pharmacogenomic biomarkers and then apply these to clinical practice will be described.
Metrics
7 Record Views
Details
- Title
- A pharmacogenomics primer
- Creators
- Michael H Court - Comparative and Molecular Pharmacogenomics Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
- Publication Details
- Journal of clinical pharmacology, Vol.47(9), pp.1087-1103
- Academic Unit
- Veterinary Clinical Sciences, Department of
- Publisher
- England
- Grant note
- GM-74369 / NIGMS NIH HHS GM-61834 / NIGMS NIH HHS
- Identifiers
- 99900548596501842
- Language
- English
- Resource Type
- Journal article